Sartorius Supports Coronavirus Vax Candidate

03.25.20

BIOSTAT STR single-use bioreactor system used for the upstream preparation of the recombinant vaccine

Sartorius has supported CanSino Biologics Inc. and the Institute of Bioengineering in China in their development of the first vaccine candidate against the novel coronavirus to enter clinical trials. CanSinoBIO and the Institute of Bioengineering used Sartorius’ BIOSTAT STR single-use bioreactor system for the upstream preparation of the recombinant vaccine, and rapid linear amplification of the adenovirus vector (Ad5-nCoV).


The BIOSTAT STR single-use bioreactor system comes with updated BioPAT toolbox for process monitoring, as well as Flexsafe STR integrated, single-use bioprocess bags. It has been used for vaccine manufacturing because it offers rapid scalability and flexibility to adapt to fluctuating demand. The single use bags prevent cross-contamination and reduce the time needed to prepare a vector for a vaccine, from several months to several weeks, when compared to stainless steel bioreactors.

“We are pleased that we can help our clients and partners accelerate vaccine development while maintaining compliance with safety protocols, thereby allowing us to contribute to better health for more people,” said Huang Xian, Head of Marketing at Sartorius BPS China. “The Sartorius team is making every effort to quickly allocate the staff and equipment needed to support the early stages of vaccine development during this high-risk period. We hope that Ad5-nCoV will achieve approval as early as possible, so it can help stop the spread of the novel coronavirus worldwide.”

This is the second collaboration from Sartorius, CanSinoBIO, and the Institute of Bioengineering to accelerate vaccine development. In October 2017, Sartorius’ BIOSTAT STR50 bioreactor system was used during CanSinoBIO’s and the Institute of Bioengineering’s joint development of a recombinant vaccine against Ebola virus disease. This was the first registered Ebola vaccine in the world.